Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q8WYH8
UPID:
ING5_HUMAN
Alternative names:
p28ING5
Alternative UPACC:
Q8WYH8; A8K1P3; Q53NU6; Q57Z54; Q9BS30
Background:
Inhibitor of growth protein 5, known as p28ING5, plays a crucial role in cellular processes through its involvement in the HBO1 complex and the MOZ/MORF complex. It mediates specific acetylation of histones H3 and H4, influencing chromatin structure and thereby regulating DNA replication and transcriptional coactivation. Additionally, p28ING5 has been shown to inhibit cell growth, delay S-phase progression, and enhance Fas-induced apoptosis, highlighting its potential impact on cell cycle regulation and apoptosis.
Therapeutic significance:
Understanding the role of Inhibitor of growth protein 5 could open doors to potential therapeutic strategies. Its involvement in critical cellular processes such as DNA replication, transcriptional coactivation, and apoptosis regulation underscores its potential as a target for therapeutic intervention in diseases where these processes are dysregulated.